BioWorld BioWorld MedTech BioWorld Asia BioWorld Science

BioWorld

Street can a-GRI on phase IIb safety win in IPF with tazarotene
GRI Bio Inc.’s oral version of tazarotene is showing phase IIa promise in idiopathic pulmonary fibrosis (IPF). The peek at interim safety with the compound, a RAR-βɣ dual...

More in BioWorld

BioWorld MedTech

Hospitalizations decline shows clearer benefit in Triclip study
The two-year results of TRILUMINATE trial showed the first objective benefit to use of Abbott Laboratories’ Triclip transcatheter tricuspid edge-to-edge repair device in a...

More in BioWorld MedTech

BioWorld Science

Combining antibody domain, NA-targeting drug makes for broad-spectrum antibody
The ability of influenza virus to rapidly undergo antigenic shift to evade immunity raises the need for effective influenza antivirals with a broad spectrum. In a recent Na...

More in BioWorld Science

BioWorld Asia

Merck opts in for global license of Abbisko’s pimicotinib for $85M
Merck KGaA is exercising its option for a global license to commercialize Abbisko Therapeutics Co. Ltd.’s pimicotinib for $85 million. As previously reported by BioWorld,...

More in BioWorld Asia

BioWorld Insider Podcast

As biopharma investments stumble, med tech surges: This year’s med-tech investments include $2.76B via 56 transactions in January alone. BioWorld MedTech Editor Annette Boyle discusses why the sector is performing well year to date.